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ABSTRACT
Introduction: This study examined the
safety, tolerability, pharmacokinetics, and
pharmacodynamics of empagliflozin, a potent
and highly selective sodium glucose
cotransporter 2 (SGLT2) inhibitor, in patients
with type 2 diabetes mellitus (T2DM).
Methods: A total of 48 patients with T2DM
were randomized to receive one of four doses of
empagliflozin (2.5, 10, 25, or 100 mg qd) or
placebo over 8 days. In every dose group, nine
patients received active drug and three received
placebo. The primary endpoint was safety
and tolerability. Pharmacokinetic and
pharmacodynamic parameters were measured
as secondary endpoints.
Results: Empagliflozin was rapidly absorbed,
reaching peak levels 1.5–3.0 h after dosing and
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showed a biphasic decline. The mean terminal
elimination half-life ranged from 10 to 19 h.
Increases in exposure (area under the plasma
concentration–time curve [AUC] and maximum
concentration of analyte in plasma [Cmax]) were
approximately proportional with dose.
Empagliflozin increased the rate and total
amount of glucose excreted in urine compared
to placebo. After administration of a single dose
of empagliflozin, cumulative amounts of
glucose excreted in urine over 24 h ranged
from 46.3 to 89.8 g, compared with 5.84 g
with placebo. Similar results were seen after
multiple doses. Fasting plasma glucose levels
decreased by 17.2–25.8% with empagliflozin
and by 12.7% with placebo. The frequency of
adverse events was 33.3–66.7% with
empagliflozin and 41.7% with placebo. There
were no changes in urine volume or micturition
frequency under the controlled study
conditions.
Conclusion: Overall, pharmacokinetic
assessments demonstrated a dose-proportional
increase in drug exposure and support once-
daily dosing. Elevated urinary glucose excretion
was observed with all doses. Multiple once-daily
oral doses of empagliflozin (2.5–100 mg)
reduced plasma glucose and were well
tolerated in patients with T2DM. EudraCT
(2007-000654-32).




Traditional approaches to the treatment of type
2 diabetes mellitus (T2DM) have focused
on improving insulin secretion and insulin
sensitivity with the aim of lowering blood
glucose levels to meet glycosylated
hemoglobin (HbA1c) targets while avoiding
hypoglycemia [1, 2]. However, evidence
suggests that only around half of patients
achieve an HbA1c target of less than 7% [3].
Recent studies report limited benefits of
intensive glucose lowering on mortality and
cardiovascular outcomes in patients with T2DM
[4–8]. Therefore, future management strategies
should address features beyond glucose control
[9, 10].
Sodium glucose cotransporter 2 (SGLT2)
inhibitors are a promising new class of
compounds in development that offer an
alternative mechanism for control of
hyperglycemia in T2DM by reducing glucose
reabsorption in the kidney and thereby
increasing urinary glucose excretion (UGE)
[11–13]. Clinical studies of SGLT2 inhibitors
have demonstrated glucose lowering efficacy, a
favorable safety profile, and beneficial effects on
weight, blood pressure, and other metabolic
parameters [14–19].
Empagliflozin is an SGLT2 inhibitor in
development as a treatment for T2DM. In
in vitro studies, empagliflozin exhibited
highly potent inhibition of SGLT2 (half
maximal inhibitory concentration [IC50] of
3.1 nM [pIC50 (SE) 8.5 (0.02) nM]), with a
[2,500-fold selectivity for SGLT2 over SGLT1
[20]. Single oral doses of empagliflozin were
well tolerated in healthy volunteers resulting
in dose-dependent UGE without inducing
hypoglycemia [21]. The objective of this
multiple ascending dose study, the first study
of empagliflozin in patients with T2DM,
was to assess the safety, tolerability,
pharmacokinetics, and pharmacodynamics of
multiple rising doses of empagliflozin in this
patient population.
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Study Design
This was a multiple rising dose, randomized,
double-blind trial with within-group placebo
control. Patients were randomized upon
admission to the trial center to one of four
doses of empagliflozin (2.5, 10, 25, and
100 mg), which were tested sequentially in
ascending order of dose. Within every dose
group, patients were randomized 3:1 to receive
active drug or placebo. Treatment allocation
was carried out according to a randomized list
of patient and medication numbers. Within
each dose group, patients were randomized to
receive placebo or active drug and patients and
investigators were double blinded until the
study had completed. Patients and investigators
were aware of the dosing stage (but not if patients
were receiving placebo).
Patients received a single dose on day 1 and
once-daily dosing on days 3–9. The dosing on
day 2 was skipped to allow estimation of the
terminal elimination half-life after a single dose
to compare with the steady state half-life. Study
drug was administered at the same time every
day with 240 mL of water. Patients were fasted
overnight for 10 h on days -2, -1, 1, 8, and 9.
An end-of-study examination was carried out in
the 1-week post-treatment period (days 15–21).
An oral glucose tolerance test (OGTT;
administration of 75 g glucose solution after
overnight fasting) was performed on days -1, 1,
and 9.
Subjects
The trial was conducted at the Profil Institute
for Metabolic Research, Neuss, Germany.
Eligible subjects were patients with T2DM
treated with diet and exercise only or B2 oral
anti-diabetic agents with at least one agent
taken at B50% of its maximum dose; HbA1c
B8.5% at screening; and body mass index
(BMI) 18.5–40 kg/m2. Patients on insulin or
thiazolidinediones were excluded, as were
patients with high fasting [ 240 mg/dL
(13.3 mmol/L)] or postprandial [ 400 mg/dL
([22 mmol/L)] blood glucose and patients
with clinically significant concomitant diseases
or abnormalities in the screening laboratory.
Evaluations
The primary endpoint was safety and
tolerability. Safety parameters, including
adverse events (AEs), electrocardiogram (ECG),
vital signs, physical examination, and
laboratory parameters in blood and urine
samples, were measured throughout the study.
Meals and fluid intake were standardized during
the in-house period of the study (from day -2
to day 9).
Secondary endpoints were pharmacokinetic
and pharmacodynamic parameters.
Pharmacokinetic endpoints included mean
plasma concentration time profiles of
empagliflozin, maximum concentration of
analyte in plasma (Cmax), time to reach peak
levels (tmax), terminal elimination half-life (t1/2),
apparent terminal rate constant (kz), area under
the plasma concentration–time curve (AUC),
renal clearance (CLR) and the fraction of the
dose that was excreted unchanged in urine (fe).
Pharmacodynamic measurements included
UGE, 8-point weighted mean daily glucose
(MDG), and fasting plasma glucose (FPG).
Samples for the determination of analyte
plasma concentrations were drawn before drug
administration on days -2, -1, 1, 2, 3, and 5–9,
at time points up to 48 h after dosing on day 1,
and up to 72 h after dosing on day 9. On days
-2, -1, 1, 8, and 9 all urine voided over a period
of 24 h (48 h for day 1 and 72 h for day 9) was
collected for UGE measurements. Urine samples
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collected on days 1 and 9 were also used for
pharmacokinetic measurements.
Empagliflozin concentrations in plasma and
urine were analyzed using a validated high
performance liquid chromatography, tandem
mass spectrometry (HPLC–MS/MS) assay with a
lower limit of quantification of 1.11 nmol/L
(0.5 ng/mL) for plasma, or 4.44 nmol/L
(2 ng/mL) for urine. Pharmacokinetic parameters
were calculated using WinNonlinTM software (v5.2,
Pharsight Corporation, Mountain View, CA, USA).
Mean plasma concentration–time profiles of
empagliflozin were calculated only if at least 2/3
of the individual patient concentrations at each
time point were above the limit of quantification
(1.1 nM empagliflozin). Cmax and tmax values
were directly determined from the plasma
concentration–time profiles of each subject. The
t1/2 was calculated as the quotient of the natural log
(ln)(2) and kz. The kz was estimated from a
regression of ln(C) versus time over the terminal
log-linear drug disposition portion of the
concentration–time profiles. AUC to the last
quantifiable time point was calculated using the
linear trapezoidal method for ascending
concentrations and the log trapezoidal method for
descending concentrations. CLR was determined as
the quotient of the amount of drug excreted
unchanged in urine over AUC. The fe was
determined by the quotient of the sum of drug
excreted over all dosing intervals and the dose
administered.
Mean cumulative UGE over 24 h (Ae0–24) was
measured after single doses of empagliflozin
with OGTT (day 1) and after multiple doses after
fasting (day 8) or with OGTT (day 9). Weighted
MDG was estimated by dividing the area under
the 24-h glucose curve (AUEC0–24) by 24 h.
Inhibition of glucose reabsorption was
calculated by comparing renal tubular glucose
reabsorption rate (TG) on day 8 with day -2 as
baseline. TG was calculated as the difference
between filtered load (FL) and glucose excretion
rate (ER). The FL was calculated as the product
of estimated glomerular filtration rate (eGFR)
and plasma MDG. ER was estimated by dividing
the cumulative amount of glucose excreted in
urine (UGE) over a dosing interval by 24 h.
MDG measurements were performed during the
OGTT on days -1, 1, and 9, and under ‘normal’
trial conditions (standardized meals without
OGTT) on days -2 and 8. The impact of
empagliflozin on postprandial glucose (PPG)
levels was analyzed from the area under the
glucose concentration–time curve AUEC 1–5 h
(AUEC1–5) after OGTT.
Statistical Analysis
Safety variables, pharmacokinetic and
pharmacodynamic parameters were evaluated
by descriptive statistical methods. Safety and
pharmacodynamic analyses were based on the
randomized set, which was identical to the
treated set and included all 48 patients treated
with active drug or placebo. Pharmacokinetic
analyses were based on the pharmacokinetic set,
which included all 36 patients treated with
active drug. Attainment of steady state using
trough concentrations between days 5 and 9
was analyzed using a repeated measures linear
model on the logarithmic scale including
‘patient’ as a random effect and ‘time’ as a
repeated effect. Dose proportionality was
explored using a regression model applied to
log-transformed data. UGE, weighted MDG, and
FPG were analyzed daily for change from
baseline using an analysis of covariance
(ANCOVA) model. The effect ‘patient’ was
considered random while the effect ‘treatment’
was considered fixed. The baseline value was
included as a continuous covariate. Statistical
analysis utilized SAS statistics software version
8.2 (SAS Institute Inc. Cary, NC, USA).




Seventy-four patients were screened and 48 (39
white males, 8 white females, 1 black female)
were randomized (12 to each dose group, with 9
patients randomized to receive empagliflozin
treatment and 3 to placebo). All randomized
patients received at least 1 dose of study drug;
46 patients received 8 doses of empagliflozin or
placebo over 8 days, 1 patient received 6 doses
of placebo over 6 days, and 1 patient received 2
doses of empagliflozin over 2 days. Forty-six
patients completed the study, with 2 patients
discontinuing treatment prematurely due to
adverse events. Baseline characteristics are
summarized in Table 1.
Safety and Tolerability
In total, 24 (50.0%) patients experienced AEs
during the treatment period. No AEs were
reported in the 1-week post-treatment period.
The frequency of AEs was 52.8% in patients
receiving empagliflozin treatment and 41.7%
with placebo. The most frequently reported AE
was headache, reported by 4 patients (8.3%)
during the treatment period, occurring in 0–2










Patients, N (%) 12 (100.0) 9 (100.0) 9 (100.0) 9 (100.0) 9 (100.0) 48 (100.0)
Gender, N (%)
Male 10 (83.3) 7 (77.8) 8 (88.9) 7 (77.8) 7 (77.8) 39 (81.3)
Female 2 (16.7) 2 (22.2) 1 (11.1) 2 (22.2) 2 (22.2) 9 (18.8)
Ethnicity, N (%)
White 12 (100.0) 9 (100.0) 9 (100.0) 9 (100.0) 8 (88.9) 47 (97.9)
Black 0 0 0 0 1 (11.1) 1 (2.1)
Age, years, median (range) 59.0 (51–67) 57.0 (37–67) 57.0 (33–66) 58.0 (40–68) 61.0 (50–68) 57.5 (33–68)
Weight, kg, median (range) 100.6 (69.5–118.4) 100.1 (84.2–112.9) 101.7 (71.5–122.8) 91.1 (67.2–121.4) 85.4 (71.2–100.1) 94.3 (67.2–122.8)
BMI, kg/m2,median (range) 32.9 (24.3–38.7) 31.9 (28.8–34.3) 30.3 (25.3–39.2) 31.5 (26.3–36.3) 27.6 (23.9–32.0) 31.1 (23.9–39.2)
Duration of diabetes, years,
mean (SD)
4.7 (2.4) 5.5 (3.9) 4.9 (2.9) 7.6 (5.1) 9.2 (6.8) 6.3 (4.5)
Fasting plasma glucose,
mg/dL, mean (SD)
156.9 (24.1) 144.1 (38.7) 150.1 (32.1) 142.2 (24.3) 164.3 (26.6) 151.9 (29.2)
Creatinine clearance,
mL/min, mean (SD)
103.8 (25.6) 125.3 (38.3) 78.0 (24.3) 146.8 (20.6) 117.2 (20.2) 113.6 (33.9)
Any concomitant
diagnosis, N (%)
9 (75.0) 5 (55.6) 6 (66.7) 5 (55.6) 7 (77.8) 32 (66.7)
Hypertension 7 (58.3) 3 (33.3) 4 (44.4) 4 (44.4) 5 (55.6) 23 (47.9)




11 (91.7) 8 (88.9) 9 (100.0) 8 (88.9) 7 (77.8) 43 (89.6)
Metformin 8 (66.7) 7 (77.8) 8 (88.9) 8 (88.9) 5 (55.6) 36 (75.0)
Other 3 (25.0) 1 (11.1) 1 (11.1) 0 (0.0) 3 (33.3) 7 (14.6)
Data from treated set (n = 48). All patients were treated with at least 1 dose of study medication
SD standard deviation, BMI body mass index
a Patients may have taken more than one type of concomitant anti-diabetic medication
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patients per group (Table 2). There were no
fatalities or serious AEs. A total of 16 patients
(33.3%) experienced AEs that the investigator
considered related to study medication, but
there were no treatment-related differences in
their frequency. The most common
investigator-defined treatment-related AEs
were headache, diarrhea, and hypoglycemia.
Three patients in the empagliflozin treatment
group experienced hypoglycemic events,
defined as blood glucose levels \3.5 mmol/L
(\63 mg/dL), but all of them occurred within
5 h of OGTT administration. These events were
considered by the investigator to be moderate
in intensity, but all patients recovered following
therapy. Two patients experienced AEs that led
to discontinuation of study treatment [1 patient
in the placebo group had an increase in hepatic
enzymes (maximum alanine transaminase level
of 335 U/L) considered to be of severe intensity
and 1 patient treated with empagliflozin
experienced cellulitis (phlegmon of the lower
left arm) considered to be of moderate intensity,
which the investigator did not believe to be
related to the study medication]. No urinary
tract or genital tract infections were reported.
There were no findings of clinical significance
in the laboratory clinical evaluations (including
electrolytes and lipid parameters; Table 3),
12-lead ECG, vital signs, weight, or waist
circumference. No major differences in total
urine volume were observed between the
empagliflozin and placebo groups. On day 8,
the mean volume of urine collected ranged
from 2.36 to 4.08 L following empagliflozin
dosing, compared with a mean of 3.23 L for
the placebo group. Similarly, there were no
changes to micturition frequency after
empagliflozin administration compared with
placebo under the controlled fluid intake
conditions of the trial (Table 4). Creatinine
clearance was similar in all dose groups except
for the 2.5 mg empagliflozin dose group at
166 h (Table 5). In this group, two patients
had high derived creatinine clearance values
in urine fractions collected over a 2-h period
pre-dose on day 8 (1,392 mL/min 9 1.73 m2 and
1,124 mL/min 9 1.73 m2 change from
baseline), based on urinary creatinine
concentrations of 251 mg/dL in a volume of
670 mL and 84.1 mg/dL in a volume of
2,115 mL of urine, respectively, and plasma
creatinine concentrations of 0.68 mg/dL and
0.94 mg/dL, respectively. This resulted in
a mean (SD) change from baseline in
derived creatinine clearance of 360




2.5 mg qd N5 9
Empagliﬂozin
10 mg qd N5 9
Empagliﬂozin
25 mg qd N5 9
Empagliﬂozin
100 mg qd N5 9
Patients with
any AE
5 (41.7) 6 (66.7) 5 (55.6) 5 (55.6) 3 (33.3)
Headache 1 (8.3) 0 1 (11.1) 2 (22.2) 0
Diarrhea 1 (8.3) 2 (22.2) 0 0 0
Pruritus 1 (8.3) 1 (11.1) 0 1 (11.1) 0
Hypoglycemia 0 0 2 (22.2) 1 (11.1) 0
Data from the treated set (n = 48)
AE adverse event
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(620) mL/min 9 1.73 m2 in the 2.5 mg
empagliflozin group at 166 h, compared with
-12.1 (54.6) mL/min 9 1.73 m2 for the placebo
group (Table 5).
Pharmacokinetics
Empagliflozin was rapidly absorbed after oral
administration, reaching peak levels between 1.5
Table 3 Mean (SD) electrolyte and lipid measurements at baseline and last value on treatment
Placebo N 5 12 Empagliﬂozin
2.5 mg qd N 5 9
Empagliﬂozin
10 mg qd N 5 9a
Empagliﬂozin
25 mg qd N 5 9
Empagliﬂozin

















Sodium 140 (3) 140 (3) 140 (2) 140 (2) 141 (1) 140 (1) 139 (2) 139 (2) 138 (2) 139 (2)
Potassium 4.3 (0.4) 4.4 (0.4) 4.1 (0.3) 4.2 (0.3) 4.2 (0.2) 4.4 (0.3) 4.1 (0.2) 4.1 (0.3) 4.5 (0.4) 4.5 (0.3)
Calcium 2.3 (0.1) 2.3 (0.1) 2.3 (0.1) 2.3 (0.1) 2.3 (0.1) 2.3 (0.1) 2.3 (0.1) 2.3 (0.1) 2.4 (0.1) 2.3 (0.1)
Total cholesterol
(mg/dL)
179 (16) 173 (7) 181 (9) 175 (11) 173 (27) 171 (25) 185 (15) 174 (13) 181 (9) 174 (11)
HDL-cholesterol
(mg/dL)
43 (22) 31 (16) 15 (21) 16 (18) 46 (29) 31 (18) 47 (12) 41 (17) 42 (19) 37 (18)
Triglycerides (mg/dL) 177 (121) 143 (89) 249 (109) 171 (65) 194 (145) 114 (42) 141 (67) 89 (26) 157 (43) 97 (27)
Values are normalized to a standard reference range
SD standard deviation, HDL high-density lipoprotein
a N = 8 for HDL-cholesterol
Table 4 Mean day (07:00–18:59) and night (19:00–06:59) micturition frequency at baseline and on day 1, day 8 and day 9







Day 1 Day 8 Day 9
Mean (SD) micturition day frequency
Placebo 12 4.8 (1.5) 8.5 (2.4) 8.1 (2.3) 8.9 (2.8)
2.5 mg qd 9 3.9 (0.8) 6.0 (1.2) 6.6 (1.8) 6.4 (1.9)
10 mg qd 9 3.8 (1.1) 8.3 (1.7) 6.8 (1.6) 8.9 (1.7)
25 mg qd 9 4.4 (1.8) 7.8 (2.6) 7.0 (1.6) 8.2 (2.0)
100 mg qd 9 4.1 (0.8) 7.9 (2.4) 6.9 (1.5) 8.4 (2.5)
Mean (SD) micturition night frequency
Placebo 12 3.5 (1.8) 4.2 (1.6) 5 (1.3) 3.8 (1.0)
2.5 mg qd 9 3.2 (0.5) 3.7 (1.5) 3.7 (1.2) 3.4 (1.3)
10 mg qd 9 3.2 (0.7) 3.8 (0.8) 4.0 (1.7) 3.7 (0.5)
25 mg qd 9 3.6 (2.0) 4.3 (1.0) 4.8 (1.6) 4.1 (1.4)
100 mg qd 9 3.0 (0.9) 3.6 (1.1) 4.7 (1.5) 3.7 (1.0)
Data from the treated set (n = 48)
SD standard deviation
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and 3 h after a single dose, thereafter, plasma
levels declined in a biphasic fashion with a rapid
distribution phase and slower elimination phase
(Fig. 1). Both AUC and Cmax increased
approximately proportionally with dose over
the dose range from 2.5 to 100 mg (Table 6).
After repeated dosing, trough concentrations
were similar on days 5–8, indicating that steady
state was reached by day 5. At steady state,
empagliflozin concentration–time profiles
showed a trend similar to single dose profiles on
day 1 (Fig. 1) [note, 2 patients (1 each from the
10 mg and 100 mg dose groups on day 9) were
excluded due to incomplete data or low
exposure]. The mean t1/2 after a single dose
ranged from 10.8 (25 mg dose) to 13.6 h
(100 mg dose) and was similar at steady state
(day 9; range 10.3–18.8 h) (Table 6). Consistent
with the drug’s half-life, up to 23% accumulation
of empagliflozin was observed at steady state. The
fe ranged from 12.2% to 18.7% at steady state. On
day 1, renal clearance of empagliflozin over 48 h
Fig. 1 Mean plasma concentration–time proﬁles of empagliﬂozin after multiple oral doses of 2.5–100 mg (semi-log scale).
Data from the pharmacokinetic analysis set (n = 36)
Table 5 Mean (SD) change from baseline in derived creatinine clearance at 16, 166, and 184 h after administration of






clearance (mL/min 1.73 m2)
(pre-treatment)
Change from baseline in derived
creatinine clearance (mL/min 1.73 m2)
16 h 166 h 184 h
Placebo 12a 127 (53.0) -61.2 (38.4) -12.1 (54.6) -55.4 (59.2)
2.5 mg qd 9b 108 (74.6) -57.0 (59.4) 360 (620) -20.3 (59.2)
10 mg qd 9 104 (35.8) -28.7 (34.2) 12.8 (54.7) -38.4 (36.4)
25 mg qd 9 148 (50.6) -89.2 (43.2) -40.3 (61.7) -52.4 (45.5)
100 mg qd 9 93.8 (60.4) -21.0 (59.3) -10.6 (58.0) -14.4 (55.3)
SD standard deviation
a n = 11 at 166 and 184 h
b n = 7 at 166 h
338 Diabetes Ther (2013) 4:331–345
123
(CLR, 0–48h) was 15.0–29.1 mL/min and at steady
state on day 9 (CLR,s,ss) was 23.5–34.4 mL/min
(Table 6). Overall, steady state parameters were
similar to single dose parameters, suggesting
linear pharmacokinetics with respect to time
(Table 6).
Pharmacodynamics
At all doses, oral administration of empagliflozin
increased UGE above the level of placebo, with
both the amount and rate of glucose excretion
increasing with dose. After a single dose under
OGTT conditions (day 1; Fig. 2), the amount of
glucose excreted in the urine over 24 h (Ae0–24)
was 46.3 g with 2.5 mg empagliflozin compared
with 5.84 g with placebo. There was more than a
twofold increase in UGE with the fourfold
increase in dose from 2.5 to 10 mg, in contrast
with about a 1.2-fold increase in UGE with the
fourfold dose increase in dose from 25 to 100 mg.
Glucose excretion seemed to plateau after the
10 mg dose, with total cumulative amounts
excreted ranging from 77.9 mg to 89.8 g with
10 to 100 mg empagliflozin after a single dose.
Similar results were observed after multiple doses
with or without OGTT (days 9 and 8, respectively;
Fig. 2). Empagliflozin inhibited reabsorption of
39%, 46%, 58%, and 64% of filtered glucose with
2.5, 10, 25, and 100 mg once-daily doses,
respectively (Fig. 3). The mean decrease in FPG
from baseline (day -1) to day 9 (based on least
squares means) ranged from 17.2% to 25.8% with
empagliflozin, compared with 12.7% with
placebo. The overall decline in FPG was
4.6–13.2% greater with empagliflozin than with
placebo (Fig. 4). The decrease in FPG from
baseline was significantly different compared to
placebo with the 10 mg dose (Fig. 4). A respective
decrease in plasma glucose levels was also
observed following OGTT immediately after the
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baseline (based on least squares means) was
24.1–37.0% with empagliflozin, compared with
13.5% for placebo [comparison of day 8 (without
OGTT) with baseline (day -2)] (Table 5). The
decrease in MDG from baseline was significantly
different compared to placebo with the 2.5 and
10 mg doses (Table 7). After OGTT, reductions in
plasma glucose levels in empagliflozin groups
were greater than in the placebo group. Mean
AUEC1–5 values decreased approximately
22.9–27.5% from baseline with empagliflozin,
compared with 14.2% with placebo (Table 8).
Serum insulin levels did not change to a relevant
degree (data not shown).
DISCUSSION
This randomized, double-blind, placebo-controlled
trial examined the safety, tolerability,
pharmacokinetics, and pharmacodynamics of
multiple rising doses of empagliflozin (2.5, 10,
25, and 100 mg) administered to adult patients
with T2DM. Analysis of safety data showed
that empagliflozin was well tolerated in patients
with T2DM. There were no serious AEs
associated with drug treatment and the
frequency of AEs with empagliflozin treatment
was similar to placebo. Importantly, plasma
glucose was lowered in the absence of
non-OGTT-related episodes of hypoglycemia.
Furthermore, there were no safety findings
of concern, with no clinically significant
changes observed in creatinine clearance,
urine volume or micturition frequency
following empagliflozin administration under
Fig. 2 Mean (SD) cumulative urinary glucose excretion (UGE) over 24 h (Ae0–24) after single (day 1) and multiple (day 8
and 9) oral doses of empagliﬂozin or placebo. Data from the treated set (n = 48)
Fig. 3 Mean (SD) percent inhibition of glucose reabsorp-
tion on day 8 following multiple oral administrations of
empagliﬂozin (2.5–100 mg) once daily. Data from the
treated set (n = 48)
340 Diabetes Ther (2013) 4:331–345
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the controlled fluid intake conditions of the
trial, indicating that increased UGE is unlikely
to affect renal function as assessed by these
measures. No urogenital infections were
observed in this short-term study. More long-
term studies in patients with T2DM will
Table 7 Mean (SD) weighted MDG at baseline and after administration of oral empagliﬂozin doses (2.5–100 mg) without





Mean MDG (SD) mg/dL
Baseline
(day 22)





Placebo 12a 169 (30.5) 153 (24.5) -13.5
2.5 mg qd 9 161 (57.3) 134 (42.7) -29.0 -15.5, p\0.05
10 mg qd 9b 160 (35.8) 124 (18.9) -37.0 -23.5, p\0.01
25 mg qd 9 159 (32.8) 133 (36.2) -28.5 -15.0, p = 0.052
100 mg qd 9 185 (33.0) 154 (17.9) -24.1 -10.6, p = 0.168
Data from the treated analysis set (n = 48). Weighted MDG, weighted mean daily glucose estimated by dividing the area
under the 24-h glucose curve by 24 h for each patient on each day
SD standard deviation
a n = 11 on day 8
b n = 8 on day 8
Fig. 4 Mean (SD) changes from baseline (day -1) in fasting plasma glucose (FPG) after treatment with multiple doses of
empagliﬂozin or placebo (day 9). Data from the treated set (n = 48)
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provide more information on the safety and
tolerability of empagliflozin.
Pharmacokinetic data demonstrated that
oral doses of empagliflozin were rapidly
absorbed, reaching steady state by day 5 with
moderate accumulation. There was a rapid
distribution phase and a slower elimination
phase, with dose-proportional increases in
exposure and a terminal elimination half-life
of 10–19 h. These results are consistent with
those from a single rising dose study
conducted in healthy volunteers [21], which
demonstrated approximately dose-proportional
increases in exposure and a terminal
elimination half-life of 8.6–13 h. These
pharmacokinetic features demonstrate the
suitability of empagliflozin for once-daily
dosing in patients with T2DM.
All doses of empagliflozin had significant
pharmacodynamic effects indicated by an
increased rate and total amount of UGE
relative to placebo. Cumulative amounts of
glucose excreted in urine over 24 h after
administration of a single dose of
empagliflozin ranged from 46 to 90 g/day in
this study, which is similar to the findings of the
single rising dose study in healthy volunteers,
in which cumulative amounts of glucose
excreted in urine in the 24 h after
administration of empagliflozin (2.5–100 mg)
ranged from 30.6 to 78.6 g/day [21]. Reports of
UGE following administration of the SGLT2
inhibitor dapagliflozin were 60 g/day in a study
of 2.5–100 mg dapagliflozin doses administered
to healthy subjects [22] and 52–85 g/day with
2.5–50 mg doses of dapagliflozin administered
to patients with T2DM [23]. Canagliflozin
treatment resulted in maximal UGE of 70 g/day
with doses of 200–800 mg qd in healthy subjects
[24]. Ipragliflozin dose dependently increased
UGE up to a maximum of approximately
59 g/day following multiple doses of 5–600 mg
in healthy volunteers and 90 g/day following
multiple doses of 300 mg in patients with T2DM
[25, 26]. However, cross-study pharmacodynamic
comparisons are difficult, as the efficacy of SGLT2
inhibitors may depend on overall glycemic
status [27].
In this study, empagliflozin inhibited
reabsorption of renally filtered glucose by
approximately 39–64% under steady state
conditions. Again, these data are comparable
Table 8 Mean (SD) glucose AUEC1–5 after an oral glucose tolerance test at baseline and after administration of oral





Mean (SD) glucose AUEC1–5 (mg h/dL)
Baseline (day 21) Day 9 Change from baseline
to day 9 (%)
Placebo 12a 970 (197) 832 (179) 14.2
2.5 mg qd 9 927 (274) 713 (216) 23.1
10 mg qd 9b 903 (201) 655 (144) 27.5
25 mg qd 9 882 (175) 679 (109) 23.0
100 mg qd 9 1,060 (225) 817 (126) 22.9
Data from the treated analysis set (n = 48)
AUEC1–5 area under the 24-h glucose concentration–time curve 1-5h, SD standard deviation
a n = 11 on day 9
b n = 8 on day 9
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with the results of the single rising dose study
[21], reporting levels of inhibition of
approximately 12–56% with single
empagliflozin doses administered to healthy
volunteers over the same dose range.
The increased UGE resulted in a substantial
decrease in both FPG and PPG and therefore
also in MDG versus placebo at all doses tested.
Whereas UGE was similar after single and
multiple dosing, the plasma glucose lowering
effect of empagliflozin occurred immediately
after the first dose and increased with
treatment duration. Importantly,
empagliflozin exhibited a sustained blood
glucose lowering effect on day 10 (i.e., 1 day
after the intake of the last dose). The FPG
levels in the empagliflozin groups were at least
14% lower than on day 1, which was twice as
high as the reduction observed with placebo.
This supports the suitability of once-daily
dosing with empagliflozin.
CONCLUSION
This first trial investigating the SGLT2 inhibitor
empagliflozin in patients with T2DM
demonstrated that multiple oral doses of
empagliflozin (2.5–100 mg) increased UGE,
reduced plasma glucose and were well
tolerated in patients with T2DM.
Empagliflozin treatment resulted in significant
and clinically meaningful blood glucose
lowering effects that were apparent on the first
day of treatment, were enhanced over the
course of this (short-term) trial and lasted
beyond 24 h after intake of the last dose. The
pharmacokinetic and pharmacodynamic
properties of empagliflozin were consistent
with once-daily dosing. These results warrant
further long-term investigation of this
compound as a potential treatment for T2DM.
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